Dechra Pharmaceuticals Management

Management criteria checks 4/4

Dechra Pharmaceuticals' CEO is Ian Page, appointed in Nov 2001, has a tenure of 22.17 years. total yearly compensation is £1.04M, comprised of 59.9% salary and 40.1% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth €18.16M. The average tenure of the management team and the board of directors is 4.8 years and 4.3 years respectively.

Key information

Ian Page

Chief executive officer

UK£1.0m

Total compensation

CEO salary percentage	59.9%
CEO tenure	22.2yrs
CEO ownership	0.4%
Management average tenure	4.8yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ian Page's remuneration changed compared to Dechra Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	UK£1m	UK£621k	-UK£28m
Mar 31 2023	n/a	n/a	UK£6m
Dec 31 2022	n/a	n/a	UK£40m
Sep 30 2022	n/a	n/a	UK£49m
Jun 30 2022	UK£2m	UK£597k	UK£58m
Mar 31 2022	n/a	n/a	UK£66m
Dec 31 2021	n/a	n/a	UK£73m
Sep 30 2021	n/a	n/a	UK£64m
Jun 30 2021	UK£3m	UK£551k	UK£56m
Mar 31 2021	n/a	n/a	UK£50m
Dec 31 2020	n/a	n/a	UK£44m
Sep 30 2020	n/a	n/a	UK£39m
Jun 30 2020	UK£2m	UK£517k	UK£34m
Mar 31 2020	n/a	n/a	UK£31m
Dec 31 2019	n/a	n/a	UK£29m
Sep 30 2019	n/a	n/a	UK£30m
Jun 30 2019	UK£3m	UK£500k	UK£31m
Mar 31 2019	n/a	n/a	UK£28m
Dec 31 2018	n/a	n/a	UK£25m
Sep 30 2018	n/a	n/a	UK£30m
Jun 30 2018	UK£3m	UK£500k	UK£36m
Mar 31 2018	n/a	n/a	UK£40m
Dec 31 2017	n/a	n/a	UK£43m
Sep 30 2017	n/a	n/a	UK£35m
Jun 30 2017	UK£3m	UK£490k	UK£26m

Compensation vs Market: Ian's total compensation ($USD1.31M) is below average for companies of similar size in the German market ($USD2.91M).

Compensation vs Earnings: Ian's compensation has been consistent with company performance over the past year.

CEO

Ian Page (62 yo)

22.2yrs

Tenure

UK£1,037,000

Compensation

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ian Page	CEO, MD & Executive Director	22.2yrs	UK£1.04m	0.36% £ 18.2m
Paul Sandland	CFO & Executive Director	4.8yrs	UK£641.00k	0.010% £ 525.6k
Patrick Meeus	Chief Scientific Officer	1.5yrs	no data	no data
Jamie Adams	Chief Information Officer	1.6yrs	no data	no data
Katy Clough	Chief People Officer	no data	no data	no data
Mike Eldred	President of North America	no data	no data	no data
Melanie Hall	Company Secretary	6.5yrs	no data	no data

4.8yrs

Average Tenure

53yo

Average Age

Experienced Management: 1PK's management team is considered experienced (4.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ian Page	CEO, MD & Executive Director	26.6yrs	UK£1.04m	0.36% £ 18.2m
Paul Sandland	CFO & Executive Director	4.3yrs	UK£641.00k	0.010% £ 525.6k
Geeta Gopalan	Independent Non-Executive Director	less than a year	UK£36.00k	no data
Lawson MacArtney	Senior Independent Director	7.1yrs	UK£107.00k	0.0052% £ 263.8k
Alison Platt	Independent Non-Executive Chairman	3.8yrs	UK£207.00k	0.0033% £ 166.7k
Lisa Morrison	Designated Non-Executive Director	4.9yrs	UK£72.00k	0.0012% £ 61.9k
John Shipsey	Independent Non-Executive Director	1.6yrs	UK£73.00k	0.00053% £ 27.1k

4.3yrs

Average Tenure

59yo

Average Age

Experienced Board: 1PK's board of directors are considered experienced (4.3 years average tenure).

Dechra Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Less than half of directors are independent

Recent updates

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Investor sentiment improves as stock rises 33%

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Now 20% undervalued after recent price drop

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 22% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Now 21% undervalued after recent price drop

Less than half of directors are independent

Non-Executive Chairman recently bought €119k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Upcoming dividend of UK£0.29 per share

Board Member recently sold €1.0m worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold €1.1m worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: €41.36

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: €38.84

CEO, MD & Executive Director recently sold €12m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Upcoming Dividend of UK£0.24 Per Share

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: €38.52

Non-Executive Director recently bought €28k worth of stock

Non-Executive Director recently bought €28k worth of stock

Independent Non Executive Director recently sold €142k worth of stock

Full year earnings released - EPS €0.33

New 90-day high - €36.48

New 90-day high - €33.70

New 90-day high - €32.96

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age